Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy ...

Equities research analysts at HC Wainwright issued their FY2029 earnings estimates for Acrivon Therapeutics in a report issued on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates ...

H.C. Wainwright lowered the firm’s price target on Bitfarms (BITF) to $3.50 from $4 and keeps a Buy rating on the shares. The firm also added ...

H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on PDS Biotechnology (PDSB) to $13 from $21 and keeps a Buy rating on ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Fintel reports that on March 21, 2025, HC Wainwright & Co. downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to ...

CEO Steven Rossi emphasized that fiscal year 2024 was a transformative period for Worksport, with net sales reaching $8.4 million, representing a 455% increase from 2023. This growth was primarily ...

Plus Therapeutics' Q4 2024 earnings reveal progress with REYOBIQ nearing FDA approval & CNSide's 2025 launch. Key hires & funding bolster milestones.

today announced that members of management will present at the at the H.C. Wainwright 3 rd Annual Autoimmune & Inflammatory ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on Benitec BioPharma (NASDAQ:BNTC) shares, maintaining a $28.00 price target. The stock has shown remarkable momentum, delivering a 225% return over ...

On Monday, H.C. Wainwright reaffirmed a Buy rating on Benitec BioPharma (NASDAQ:BNTC) shares, maintaining a $28.00 price target. The stock has shown remarkable momentum, delivering a 225% return ...